Terumo Aortic's RelayPro Thoracic Stent Graft System Launched in Europe

 

April 24, 2018—Terumo Aortic announced the limited market release in Europe of its RelayPro thoracic stent graft system at the 2018 Charing Cross international symposium held April 24–27 in London, United Kingdom.

According to Terumo Aortic, the low-profile RelayPro is a next-generation device designed to expand the treatment of thoracic endovascular aortic repair to patients with smaller access vessels. The device uses the same stent design, material, and dual-sheath technology of the company's RelayPlus. With a 3- to 4-F reduction in outer profile, RelayPro delivers the accuracy and control of the RelayPlus without compromising device integrity and durability.

RelayPro is offered in a wide range of diameters, lengths, tapers, and proximal configurations. It is available in both bare stent and nonbare stent versions. Additionally, RelayPro can be individualized for the specific anatomical needs of patients.

Multiple trials are currently enrolling patients in the United States and Japan to evaluate RelayPro for treating descending thoracic aortic aneurysms, acute complicated type B thoracic aortic dissections, and blunt aortic trauma, advised Terumo Aortic.

On April 23, Terumo Aortic announced its formation with the combination of Vascutek Ltd. and Bolton Medical, Inc., subsidiaries of Terumo Corporation of Japan.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.